Achieving Lower LDL-C Levels After a Recent Myocardial Infarction Might Be Associated with Lower Healthcare Resource Use and Costs in Spain
Open accessAbstract
INTRODUCTION: There is little evidence on the relationship between achieved low-density lipoprotein cholesterol (LDL-C) levels and costs in patients on lipid-lowering therapy (LLT). We described healthcare resource use and costs (direct and indirect) by achieved LDL-C in patients receiving LLT after a recent myocardial infarction (MI) in Spain. METHODS: database; n = 1.9 million). Eligible patients were adults (≥ 18 years) hospitalized for an MI between January 2015 and December 2017, treated with a statin and/or ezetimibe, and having recorded LDL-C values at baseline and during follow-up. Healthcare resource use and direct and indirect costs (in 2018, €) were described by achieved LDL-C levels during a follow-up of 18 months. RESULTS: Of 6025 patients (mean age, 69.7 years; 77% male), only 11% achieved LDL-C goals as defined in the 2016 ESC/EAS guidelines (< 70 mg/dL), and just 1% reached the lower target (< 55 mg/dL) in the current 2019 guidelines. Achieving lower LDL-C levels translated to lower healthcare resource use and costs. Mean total (direct and indirect) costs ranged from €5044 for patients with LDL-C < 55 mg/dL to €7567 for patients with LDL-C ≥ 130 mg/dL. CONCLUSION: Very few patients achieved recommended LDL-C goals despite using LLT. Achieving lower LDL-C levels after an MI might be associated with lower healthcare resource use and costs. Use of more intensive LLT, leading to greater reductions in LDL-C, could therefore be beneficial both from a clinical and an economic perspective.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inclisiran is cost-effective in patients with FH and has potential for significant cost savings in the post-MI population.
“Taken together, these papers suggest that inclisiran is a potent LDL-C lowering therapy that has the potential of significant cost savings in the post-MI population and is cost-effective in the population with FH.”
From Small Interfering RNA for LDL-Cholesterol Reduction (2026) · cites this paper as [22]
The Discussion and Conclusions report that lower achieved LDL-C after MI might be associated with lower healthcare use and costs in Spain. The study examined patients receiving statins and/or ezetimibe, not inclisiran, so it does not establish savings from inclisiran; it also does not assess cost-effectiveness in patients with FH. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · see citing works
Halcox, J. P., Banegas, J. R., Roy, C., Dallongeville, J., De Backer, G., Guallar, E., Perk, J., Hajage, D., Henriksson, K. M., & Borghi, C. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0591-5 · Cited by 122 · see citing works
Flagged first, then by citations
Research works printed but not linked: 19
- [2]Townsend N Wilson L Bhatnagar P Wickramasinghe K Rayner M Nichols M Cardiovascular disease in Europe: epidemiological update 2016 Eur Heart J 2016 37 42 3232 3245 10.1093/eurheartj/ehw334 27523477 PMC13480964 · DOI
- [3]Mach F Baigent C Catapano AL 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur Heart J 2020 41 1 111 188 10.1093/eurheartj/ehz455 31504418 · DOI · Paper page
- [5]Roth GA Fihn SD Mokdad AH Aekplakorn W Hasegawa T Lim SS High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries Bull World Health Organ 2011 89 2 92 101 10.2471/BLT.10.079947 21346920 PMC3040378 · DOI
- [6]Reiner Ž De Backer G Fras Z Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries—findings from the EUROASPIRE IV survey Atherosclerosis 2016 246 243 250 10.1016/j.atherosclerosis.2016.01.018 26812002 · DOI
- [7]Hartgers ML Ray KK Hovingh GK New approaches in detection and treatment of familial hypercholesterolemia Curr Cardiol Rep 2015 17 12 109 10.1007/s11886-015-0665-x 26482752 PMC4611021 · DOI
- [8]Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279–89. 33580789
- [10]Sulo E Vollset SE Nygård O Trends in 28-day and 1-year mortality rates in patients hospitalized for a first acute myocardial infarction in Norway during 2001–2009: a "Cardiovascular disease in Norway" (CVDNOR) project J Intern Med 2015 277 3 353 361 10.1111/joim.12266 24815825 · DOI
- [11]Mohan KM Wolfe CD Rudd AG Heuschmann PU Kolominsky-Rabas PL Grieve AP Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis Stroke 2011 42 5 1489 1494 10.1161/STROKEAHA.110.602615 21454819 · DOI · Paper page
- [12]Bhatt DL Eagle KA Ohman EM Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis JAMA 2010 304 12 1350 1357 10.1001/jama.2010.1322 20805624 · DOI · Paper page
- [13]Smolina K Wright FL Rayner M Goldacre MJ Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010 Circ Cardiovasc Qual Outcomes 2012 5 4 532 540 10.1161/CIRCOUTCOMES.111.964700 22740013 · DOI
- [14]Danese MD Gleeson M Kutikova L Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK BMJ Open 2016 6 8 e011805 10.1136/bmjopen-2016-011805 PMC4985970 27496237 · DOI
- [15]Escobar Cervantes C Gomez-Ulloa D Elorriaga A PCV61—productivity loss and local indirect costs associated with acute coronary syndrome and stroke in Spain Value Health 2018 21 S102 10.1016/j.jval.2018.09.608 · DOI
- [19]Catapano AL Graham I De Backer G 2016 ESC/EAS guidelines for the management of dyslipidaemias Eur Heart J 2016 37 39 2999 3058 10.1093/eurheartj/ehw272 27567407 · DOI · Paper page
- [20]Charlson ME Pompei P Ales KL MacKenzie CR A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 1987 40 5 373 383 10.1016/0021-9681(87)90171-8 3558716 · DOI · Paper page
- [21]Pandor A Ara RM Tumur I Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials J Intern Med 2009 265 5 568 580 10.1111/j.1365-2796.2008.02062.x 19141093 · DOI · Paper page
- [22]Ara R Tumur I Pandor A Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation Health Technol Assess 2008 12 21 iii 10.3310/hta12210 18485273 · DOI
- [24]National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification. Clinical guideline [CG181]. https://www.nice.org.uk/guidance/cg181. Accessed 01 Mar 2022. 36952507
- [25]Allahyari A Jernberg T Hagstrom E Leosdottir M Lundman P Ueda P Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study Eur Heart J 2020 41 40 3900 3909 10.1093/eurheartj/ehaa034 32072178 PMC7654933 · DOI
- [26]Kotseva K Gerlier L Sidelnikov E Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe Eur J Prev Cardiol 2019 26 11 1150 1157 10.1177/2047487319834770 30955367 · DOI
Cited by
Sorted by citations
Small Interfering RNA for LDL-Cholesterol Reduction
Batista, F., Mamede, I., & Dacoregio, M. (2026) · JACC: Advances · doi:10.1016/j.jacadv.2026.102932
- Authors
- Escobar-Cervantes, C., Villa, G., Campos-Tapias, I., Sorio-Vilela, F., Lozano, J., Kahangire, D. A., Fernandez-Delgado, M., Sicras-Navarro, A., & Sicras-Mainar, A.
- Affiliations
- Hospital Universitario La Paz (ES)
- Amgen (Switzerland) (CH)
- Corresponding author
- Escobar-Cervantes, Carlos
- Venue
- Advances in Therapy
- Published
- 2022-06-11
- Volume
- 39
- Issue
- 8
- Pages
- 3578-3588
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- PMC
- PMC9309133
- OpenAlex
- W4282944204
- Cited by
- 6
- References
- 2
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Advances in Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Amgen (Europe) GmbH
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- LDL cholesterol, myocardial infarction, lipid-lowering therapy, statins, ezetimibe, health care utilization, health care costs, LDL cholesterol targets, treatment intensity, economic burden, Spain
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Delivery of Health Care, Female, Humans, Cholesterol, LDL, Male, Myocardial Infarction, Spain, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
